← All indications
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
Drugs by status
Approved for this indication (5)
Phase 4 trials (55)
- simvastatin
- allopurinol
- vitamin d3
- corticotropin
- insulin glulisine
- epoetin
- atenolol
- exenatide
- dulaglutide
- empagliflozin
- fexofenadine
- finerenone
- tacrolimus
- gliclazide
- liraglutide
- probucol
- amlodipine
- insulin human
- insulin degludec
- ketosteril
- lixisenatide
- niclosamide
- nisoldipine
- pirfenidone
- valsartan
- sarpogrelate
- celecoxib
- cyclosporine
- acetylsalicylic acid
- sotagliflozin
- +25 more
Phase 3 trials (23)
Phase 2 trials (68)
- metformin
- alagebrium
- calcium carbonate
- mln-1202
- azeliragon
- avenciguat
- bindarit
- ccx-140
- esaxerenone
- dw1029m
- fosinopril
- gly-230
- baricitinib
- iohexol
- Nidufexor
- ly2382770
- ly3016859
- ruboxistaurin mesylate
- mt-3995
- Narsoplimab
- ortataxel
- pamrevlumab
- pf-00489791
- pf-04634817
- ph3
- atacicept
- colchicine
- bms-813160
- formoterol
- pegloticase
- +38 more
Phase 1 trials (13)
Other trials (33)
- sucrose
- candesartan
- l-carnosine
- enalapril
- kunxian
- levocarnitine
- cyclophosphamide
- bupivacaine
- tripterygium wilfordii
- bifidobacterium bifidum
- glucagon-like peptide-1
- curcuma longa
- rhubarb extract
- triamcinolone
- pioglitazone
- oxygen
- tea
- amiloride
- edetic acid
- minocycline
- henagliflozin
- Lactobacillus acidophilus
- lactobacillus casei
- rutin
- casein
- gemigliptin
- epalrestat
- cocoa extract
- lactobacillus rhamnosus
- beraprost
- +3 more
Organizations
Organization Involved with Phase 4 Indications (56)
- Abbott
- Fresenius
- Roche
- AstraZeneca
- Novo Nordisk
- Novartis
- Bayer
- Mallinckrodt
- Boehringer Ingelheim
- Otsuka
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Huazhong University of Science and Technology
- Central South University
- Korea University
- Monash University
- Seoul National University
- Stanford University
- Sichuan University
- Tanta University
- University of Groningen
- University of Saskatchewan
- University of Tehran
- Yokohama City University
- Chinese University of Hong Kong
- Columbia University
- Fudan University
- Peking University
- Southeast Renal Research Institute
- Xiamen University
- University of Colorado, Denver
- +26 more
Organization Involved with Phase 3 Indications (71)
- AbbVie
- Actelion
- Daiichi Sankyo
- Sankyo
- Fujisawa
- Gilead Sciences
- Genzyme
- Wyeth
- Grupo Medifarma, S. A. de C. V.
- Hamad Medical Corporation
- Hannover Clinical Trial Center GmbH
- Kyowa Hakko Kirin
- Speedel Pharma Ltd.
- Neovii Biotech
- NephroGenex, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University College Dublin
- Aarhus University
- Ain Shams University
- BCDiabetes.Ca
- Cornell University
- Duke University
- EUROSPK Study Group
- Emory University
- University of Washington
- Gottfried Wilhelm Leibniz Universität Hannover
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Joslin Diabetes Center
- Melbourne Health
- Nanjing Medical University
- +41 more
Organization Involved with Phase 2 Indications (68)
- CSL Behring
- Incyte
- Takeda
- Celgene
- Relypsa
- Bristol-Myers Squibb
- Ironwood Pharmaceuticals
- Eli Lilly
- Exelixis
- Genentech
- Pfizer
- Angelini
- BioStratum
- ChemoCentryx
- Chromaderm, Inc.
- FibroGen
- Glycadia
- PhytoHealth Corporation
- Reata Pharmaceuticals, Inc.
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Vascular Pharmaceuticals, Inc.
- Concert Pharmaceuticals
- Fuji Yakuhin Co., Ltd.
- Genkyotex Innovation SAS
- Synvista Therapeutics, Inc
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
- Al-Ahliyya Amman University
- NHS Blood and Transplant
- Queen's University, Belfast
- +38 more
Organization Involved with Phase 1 Indications (18)
- Anhui Medical University
- China Academy of Chinese Medical Sciences
- Kunming Medical University
- Shanghai University of Traditional Chinese Medicine
- Capital Medical University
- Zhengzhou University
- Frontage Laboratories, Inc.
- Baodin City Hospital of Traditional Chinese Medicine
- Shijiazhuang City Hospital of Traditional Chinese Medicine
- Zouping Country Hospital of Traditional Chinese Medicine
- Changchun Hospital of Traditional Chinese Medicine
- Xingtai City Hospital of Traditional Chinese Medicine
- Medicine Zibo Wanjie Tumor Hospital
- She Country Hospital of Traditional Chinese Medicine
- Baishi Hospital
- Guangzhou Pharmaceucal Company Limited
- Hubei University of Chinese Medicine
- Regenerative Medicine Minnesota
Organization Involved with Other Experimental Indications (49)
- Astellas
- Danish Heart Foundation
- Chang Gung University
- Harvard University
- Federal University of Rio Grande do Sul
- Kanazawa University
- Los Angeles Biomedical Research Institute
- Nanjing University
- Osaka University
- Providence Health & Services
- Shaheed Faghihi Hospital
- Shiga University
- Texas Tech University
- Universidad Autonoma de Nuevo Leon
- University of South Carolina
- University of Southern Denmark
- Wake Forest University
- Wuhan University
- Chongqing Medical University
- Nazareth Hospital
- Medical University of South Carolina
- The Nazareth Hospital, Israel
- Nazareth EMMS Hospital
- Western Galilee Hospital
- Hennepin Healthcare
- Hyogo Medical University
- Tsukiwa-machi, Seta, Otsu, Shiga, Japan
- University of Nice Sophia Antipolis
- Hallym University
- Technical University of Dresden
- +19 more